Clinical & Molecular Endocrinology – January 2016 - View Full PDF
Faramarz Ismail-Beigi, MD, PhD
Clinical and Molecular Endocrinology, UH Case Medical Center; Professor of Medicine, Case Western Reserve University School of Medicine
Faramarz Ismail-Beigi, MD was a principal investigator on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which found that intensively targeting blood sugar in adults with type 2 diabetes who are also at high risk for heart attack and stroke does not significantly reduce the risk of major cardiovascular events, but does increase risk of death compared with standard treatment.
Building on these findings, the Action to Control Cardiovascular Risk in Diabetes Follow On (ACCORDION) clinical trial is an observational study of at least 8,000 participants of the ACCORD trial, which ended in 2009. ACCORDION is designed to further research the long-term effects of the ACCORD treatment strategies and the relationships among various cardiovascular and diabetic risk factors. Dr. Ismail-Beigi is currently leading a new NIH-sponsored clinical trial, The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). It is a long-term study of different treatments for type 2 diabetes.
To learn more about the ACCORD research, contact Dr. Ismail-Beigi at Faramarz.Ismail-Beigi@UHhospitals.org
All National Institutes of Health (NIH) funding for basic and clinical research is awarded to the School of Medicine at Case Western Reserve University